Understanding how chromatin signaling affects gene regulation and disease
Official title: Molecular mechanisms of chromatin signaling and epigenetic regulation
Funded at Van Andel Research Institute · NIH-11141646 · Data updated 2026-11-12
This study is looking at how changes in our DNA and the proteins around it can affect how our cells work and lead to diseases like cancer, with the hope of finding new ways to treat these conditions.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Van Andel Research Institute NIH-funded |
| Lab location | 1 site (Grand Rapids, United States) |
| Project start | August 1, 2024 |
| Project end | May 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $518,400 |
| NIH project number | 5R35GM152184-02 |
| Project ID | NIH-11141646 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with cancers or other diseases characterized by epigenetic alterations.
✕Less likely to help
Patients with conditions unrelated to chromatin signaling or epigenetic regulation may not benefit from this research.
What this research studies
This research investigates the molecular mechanisms behind chromatin signaling and epigenetic regulation, focusing on how changes in DNA methylation and histone modifications influence cellular functions and contribute to diseases like cancer. By employing advanced biochemical, genomic, and proteomic technologies, the research aims to uncover the precise ways these epigenetic signals operate and their impact on chromatin structure and function. The ultimate goal is to translate these findings into new treatment strategies for various human diseases.
Why it matters
Potential benefit: If successful, this research could lead to innovative therapies that target epigenetic changes in diseases, potentially improving treatment outcomes for patients.
How similar studies have gone: Previous research has shown promising results in understanding epigenetic regulation, suggesting that this approach could lead to significant advancements in treatment strategies.
Where this research is happening
-
Van Andel Research Institute
Grand Rapids, United States Active
Researchers
- Principal investigator: Rothbart, Scott — Van Andel Research Institute
- Study coordinator: Rothbart, Scott
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.